Scarica l'app Stockscreener
3.44
1.99%
-0.07
Pre-mercato:
3.34
-0.10
-2.91%
Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie
SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey
SABS Technical Analysis & ETF Price Forecast - Intellectia AI
SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SAB Biotherapeutics Inc (SABS) Balance Sheet - TradingKey
SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SAB Biotherapeutics Inc (SABS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
SABS|SAB Biotherapeutics Inc|Price:3.510|Chg%:-0.070 - TradingKey
SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABSW - TradingView
SAB Biotherapeutics (SABS) Slides 3.4% as Stock Tests Key Support LevelsPositive Gamma - dars.gov.et
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment - Yahoo Finance
SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jul 2026 $SABS - MarketBeat
SAB Biotherapeutics (SABS) Edges Lower as Stock Tests Key Support LevelsCorrective Wave - DonanımHaber
SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial - TipRanks
Breakthrough T1D Awards Grant for SAB-142 PRISE-hATG Study to Advance Type 1 Diabetes Therapies Beyond 100 Days Post-Diagnosis – Minichart - Minichart
Breakthrough T1D funds PRISE-hATG to study SAB-142 in Stage 3 type 1 diabetes - TradingView
Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial - Stock Titan
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes - The Manila Times
Wall Street Analysts Lift SAB Biotherapeutics Stock Over Diabetes Drug - HarianBasis.co
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? - Yahoo Finance
SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap Financial Disclosures & SEC Filings - TradingView
Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
SABSW Plunges to Penny Level as Biotech Warrant Faces Continued Selling PressureSupport Level Bounce - dars.gov.et
Barclays Initiates Overweight Rating on SAB Biotherapeutics, Signaling Positive Sector SentimentGross Profit Margin - dars.gov.et
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Microcap Value Benchmark Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Value Benchmark - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell Microcap Index - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Value Benchmark - marketscreener.com
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Index - marketscreener.com
Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView
Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView
Form 4 SAB Biotherapeutics Inc For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to EBITDA forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView
[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
SAB Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:SABS) - TradingView
SABS Forecast — Price Target — Prediction for 2027 - TradingView
Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 By Investing.com - Investing.com South Africa
Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target - marketscreener.com
Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 - Investing.com
SABS Q1 2026 Earnings: EPS Misses Estimates as Operational Costs ClimbEPS Estimate Trend - dars.gov.et
Citi Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
SAB Biotherapeutics (SABS) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
SAB Biotherapeutics, Inc. 8-K SEC Filing Details for June 18, 2026: Company Information & Nasdaq Listing - Minichart
SAB Biotherapeutics Inc (SABS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SAB Biotherapeutics shareholders elect directors and approve auditor at annual meeting - Investing.com UK
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):